Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant’
Profound Medical (NASDAQ:PROF) announces the launch of its third TULSA-AI® software module, UA Alignment Assistant, designed to streamline the alignment of the ultrasound applicator during TULSA procedures. The company will showcase this innovation alongside six presentations featuring the TULSA procedure at the upcoming RSNA 2024 and SUO 2024 meetings.
The TULSA-PRO® system offers an incision-free, radiation-free treatment for various prostate conditions, including cancer and BPH. The procedure uses real-time MR guidance and precise sound absorption technology, heating targeted tissue to 55-57°C while preserving urinary continence and sexual function. The new UA Alignment Assistant module aims to improve workflow consistency by automating the MR image alignment process.
Profound Medical (NASDAQ:PROF) annuncia il lancio del suo terzo modulo software TULSA-AI®, UA Alignment Assistant, progettato per semplificare l'allineamento dell'applicatore ad ultrasuoni durante le procedure TULSA. L'azienda presenterà questa innovazione insieme a sei relazioni sul procedimento TULSA nei prossimi eventi RSNA 2024 e SUO 2024.
Il sistema TULSA-PRO® offre un trattamento senza incisioni e senza radiazioni per varie condizioni della prostata, tra cui il cancro e l'IPB. La procedura utilizza la guida MR in tempo reale e una tecnologia avanzata di assorbimento del suono, riscaldando il tessuto mirato a 55-57°C, preservando al contempo la continenza urinaria e la funzione sessuale. Il nuovo modulo UA Alignment Assistant mira a migliorare la coerenza del flusso di lavoro automatizzando il processo di allineamento delle immagini MR.
Profound Medical (NASDAQ:PROF) anuncia el lanzamiento de su tercer módulo de software TULSA-AI®, UA Alignment Assistant, diseñado para simplificar la alineación del aplicador de ultrasonido durante los procedimientos TULSA. La compañía presentará esta innovación junto con seis presentaciones sobre el procedimiento TULSA en las próximas reuniones de RSNA 2024 y SUO 2024.
El sistema TULSA-PRO® ofrece un tratamiento sin incisiones y sin radiación para diversas condiciones de la próstata, incluyendo cáncer e HBP. El procedimiento utiliza guía de resonancia magnética en tiempo real y tecnología de absorción de sonido precisa, calentando el tejido objetivo a 55-57°C mientras preserva la continencia urinaria y la función sexual. El nuevo módulo UA Alignment Assistant tiene como objetivo mejorar la consistencia del flujo de trabajo automatizando el proceso de alineación de imágenes de RM.
Profound Medical (NASDAQ:PROF)는 TULSA-AI® 소프트웨어 모듈 중 세 번째인 UA Alignment Assistant의 출시를 발표했습니다. 이 모듈은 TULSA 절차 중 초음파 적용기의 정렬을 간소화하도록 설계되었습니다. 회사는 다가오는 RSNA 2024 및 SUO 2024 회의에서 TULSA 절차에 대한 여섯 개의 발표와 함께 이 혁신을 선보일 것입니다.
TULSA-PRO® 시스템은 전립선 관련 여러 질환, incluyendo 암 및 BPH에 대한 절개 없는 방사선 없는 치료를 제공합니다. 절차는 실시간 MR 안내 및 정밀한 음파 흡수 기술을 사용하여 목표 조직을 55-57°C로 가열하며, 배뇨 기능과 성기능을 보존합니다. 새로운 UA Alignment Assistant 모듈은 MR 이미지 정렬 프로세스를 자동화하여 작업 흐름 일관성을 개선하는 것을 목표로 합니다.
Profound Medical (NASDAQ:PROF) annonce le lancement de son troisième module logiciel TULSA-AI®, l'UA Alignment Assistant, conçu pour simplifier l'alignement de l'applicateur à ultrasons lors des procédures TULSA. L'entreprise présentera cette innovation avec six présentations sur la procédure TULSA lors des prochaines réunions RSNA 2024 et SUO 2024.
Le système TULSA-PRO® offre un traitement sans incision et sans radiation pour diverses affections de la prostate, y compris le cancer et l'HBP. La procédure utilise une guidance IRM en temps réel et une technologie d'absorption sonore précise, chauffant le tissu ciblé à 55-57°C tout en préservant la continence urinaire et la fonction sexuelle. Le nouveau module UA Alignment Assistant vise à améliorer la cohérence des flux de travail en automatisant le processus d'alignement des images IRM.
Profound Medical (NASDAQ:PROF) kündigt die Einführung seines dritten TULSA-AI® Softwaremoduls, UA Alignment Assistant, an, das entwickelt wurde, um die Ausrichtung des Ultraschallgebers während TULSA-Verfahren zu optimieren. Das Unternehmen wird diese Innovation zusammen mit sechs Präsentationen zum TULSA-Verfahren auf den bevorstehenden RSNA 2024 und SUO 2024 Meetings vorstellen.
Das TULSA-PRO® System bietet eine schnittfreie und strahlenfreie Behandlung für verschiedene Prostatabedingungen, einschließlich Krebs und BPH. Das Verfahren nutzt Echtzeit-MR-Guidance und präzise Schallabsorptionstechnologie, um gezieltes Gewebe auf 55-57°C zu erhitzen, während die Harnkontinenz und sexuelle Funktion erhalten bleiben. Das neue UA Alignment Assistant Modul zielt darauf ab, die Konsistenz des Arbeitsablaufs durch Automatisierung des MR-Bildausrichtungsprozesses zu verbessern.
- Introduction of new TULSA-AI® software module to improve procedure workflow efficiency
- TULSA procedure's versatility in treating multiple prostate conditions
- Real-world efficacy data to be presented at major medical conferences
- None.
Insights
The unveiling of TULSA-AI®'s third module, UA Alignment Assistant, represents a notable advancement in prostate treatment technology. This AI-powered software enhancement streamlines the ultrasound applicator alignment process, potentially reducing procedure time and improving consistency in TULSA procedures.
The upcoming presentations at RSNA and SUO meetings will showcase real-world efficacy data from multiple prestigious institutions, including UT Southwestern Medical Center and Mayo Clinic. Of particular interest is the CAPTAIN trial update, which compares TULSA against radical prostatectomy - a critical study that could influence future treatment protocols.
The technology's versatility in treating various prostate conditions (cancer, BPH and hybrid cases) positions it well in the
TULSA procedure’s unrivaled flexibility, real-world efficacy and ongoing CAPTAIN post-market study to be featured in the scientific programs at the upcoming RSNA and SUO meetings
TORONTO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, is pleased to announce the unveiling of its third TULSA-AI® software module, UA Alignment Assistant, in addition to six presentations featuring the Transurethral Ultrasound Ablation (“TULSA”) procedure, at the upcoming 110th Scientific Assembly and Annual Meeting of the Radiological Society of North America (“RSNA 2024”) being held in Chicago, IL, December 1-4, 2024, and the 25th Annual Meeting of the Society of Urologic Oncology (“SUO 2024”) taking place in Dallas, TX, December 4 - 6, 2024.
The TULSA procedure, performed using Profound’s TULSA-PRO® system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine.
Recognizing TULSA is being used by urologists to treat an unrivalled variety of prostate cancer and/or BPH patients, Profound is developing a novel set of software modules under the TULSA-AI® brand to work in conjunction with TULSA-PRO® to provide further customizability, ease of use, speed of treatment and higher confidence in clinical outcomes.
As the name implies, UA Alignment Assistant streamlines the alignment of the ultrasound applicator (“UA”) catheter that resides in the center of the prostate during the TULSA procedure. The primary benefit of the software is improvement in workflow consistency, as instead of aligning it manually, it will now be done the same way every time via the module. Previously, the manual TULSA-PRO® UA alignment meant that users had to spend time scrolling through MR images and clicking through to align them to the UA. Via the new software, MR images will be automatically imported and then immediately displayed to the user in an aligned way.
“One of the focusses of RSNA 2024 – which is expected to attract more than 40,000 physicians, researchers and industry participants – will be on the increasingly important role that AI can play in improving the efficiency and quality of care,” said Arun Menawat, Profound’s CEO and Chairman. “Accordingly, it is the ideal forum for us to unveil for the first time our third TULSA-AI® module, UA Alignment Assistant. Effectively, the module removes a whole procedural step from TULSA, resulting in less mental charge, fewer steps to remember, and overall procedural simplification for users. We are also excited to see that the RSNA and SOU 2024 meetings will feature presentations on the TULSA procedure by esteemed physicians and researchers from the Busch Center, UT Southwestern Medical Center and the Mayo Clinic.”
Presentation details:
RSNA 2024
- Customized Whole-Gland MR-Guided Transurethral Ultrasound Ablation (TULSA) for the Treatment of Localized Prostate Cancer: A Single Centre Retrospective of 73 Patients
Joseph J. Busch, MD
Busch Center (Alpharetta, GA)
December 4, 2024; 9:00-9:30 p.m. CST
- Real-World Efficacy of MRI-Guided Transurethral Ultrasound Ablation of the Prostate: Initial Report from the Customized Ablation Registry (CARE)
Daniel N. Costa, MD
UT Southwestern Medical Center (Dallas, TX)
December 4, 2024; 12:45-1:15 p.m. CST
SOU 2024
- Real-World Efficacy of MRI-Guided Transurethral Ultrasound Ablation of the Prostate: Initial Report from the Customized Ablation Registry (CARE)
Chandler Dora, MD
Mayo Clinic (Jacksonville, FL)
December 5, 2024; 4:15-5:15 p.m. CST
- Post-Operative Sentiment in Patients After MRI-Guided Transurethral Ablation (TULSA) of Localized Prostate Cancer: Quantifiying Regret and Correlating Patient-Reported Regret with Functional Outcomes
Andrew Murphy
UT Southwestern Medical Center (Dallas, TX)
December 6, 2024; 9:00-10:00 a.m. CST
- MRI-Guided Transurethral Ultrasound Ablation (TULSA) of Localized Prostate Cancer: Single Institution Experience of Treatment Efficacy
Emily Bochner, MD
UT Southwestern Medical Center (Dallas, TX)
December 6, 2024; 9:00-10:00 a.m. CST
- CAPTAIN Randomized Controlled Trial of TULSA Against Radical Prostatectomy for Intermediate-Risk Prostate Cancer: Design and Recruitment Update
Xiaosong Meng, MD, PhD
UT Southwestern Medical Center (Dallas, TX)
December 6, 2024; 9:00-10:00 a.m. CST
About Profound Medical Corp.
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO® system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
Forward-Looking Statements
This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer, BPH, uterine fibroids, palliative pain treatment and osteoid osteoma; and the success of Profound’s U.S. commercialization strategy and activities for TULSA-PRO®. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, regulatory approvals, reimbursement, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.
For further information, please contact:
Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849
Susan Thomas
Public Relations
sthomas@profoundmedical.com
T: 619.540.9195
FAQ
What is the new TULSA-AI® module announced by Profound Medical (PROF) in November 2024?
What conditions can the TULSA-PRO® system treat?
Where will Profound Medical (PROF) present its TULSA procedure findings in December 2024?
